J Gynecol Oncol.  2013 Oct;24(4):291-292. 10.3802/jgo.2013.24.4.291.

Squamous cell carcinoma antigen in cervical cancer and beyond

• Kim BG

• KMID: 2177865
• DOI: http://doi.org/10.3802/jgo.2013.24.4.291

Abstract

No abstract available.

MeSH Terms

Antigens, Neoplasm
Carcinoma, Squamous Cell
Serpins
Uterine Cervical Neoplasms
Antigens, Neoplasm
Serpins

Reference

1. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977; 40:1621–1628.

2. Maruo T, Yoshida S, Samoto T, Tateiwa Y, Peng X, Takeuchi S, et al. Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. Tumour Biol. 1998; 19:494–504.

3. Gadducci A, Tana R, Fanucchi A, Genazzani AR. Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol. 2007; 107:S23–S26.

4. Bolger BS, Dabbas M, Lopes A, Monaghan JM. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol. 1997; 65:309–313.

5. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol. 1996; 14:111–118.

6. Strauss HG, Laban C, Lautenschlager C, Buchmann J, Schneider I, Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer. 2002; 38:1987–1991.

7. Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol. 2005; 23:1455–1462.

8. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41:823–830.

9. Kawaguchi R, Furukawa N, Kobayashi H, Asakawa I. Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J Gynecol Oncol. 2013; 24:313–320.

10. An JJ, Lee YY, Park JY, Choi CH, Kim TJ, Lee JW, et al. Prognostic value of pre-treatment SCC-Ag level in patients with cervical cancer. Korean J Obstet Gynecol. 2011; 54:428–434.

11. Esajas MD, Duk JM, de Bruijn HW, Aalders JG, Willemse PH, Sluiter W, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001; 19:3960–3966.

12. Shimura K, Mabuchi S, Yokoi T, Sasano T, Sawada K, Hamasaki T, et al. Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice. J Gynecol Oncol. 2013; 24:321–329.

13. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008; 66:10–20.

14. Lai CH, Yen TC, Ng KK. Molecular imaging in the management of cervical cancer. J Formos Med Assoc. 2012; 111:412–420.